PCV-10 vax cost effective vs PCV-13

June 2011
PharmacoEconomics & Outcomes News;6/25/2011, Issue 631, p7
The article discusses a cost-utility analysis conducted in an Argentine healthcare system in 2011 which shows that pneumococcal 10-valent vaccine conjugate (PCV-10) is better value for money for routine child immunisation than pneumococcal 13-valent-CRM197 vaccine conjugate (PCV-13).


Related Articles

  • Cost a barrier for self-paid vaccination in Poland.  // PharmacoEconomics & Outcomes News;11/2/2013, Issue 690, p5 

    The article discusses the results of a study which appeared in an article by M Ganczak et al. in the October 8, 2013 issue of "Vaccine," revealing that immunisation coverage for self-paid vaccines among children aged 0-5 years in Poland is largely shaped by the cost of the vaccine.

  • Recommended Childhood and Adolescent Immunization Schedule/ United States, 2003.  // MMWR: Morbidity & Mortality Weekly Report;1/31/2003, Vol. 52 Issue 4, pQ1 

    Presents information on the recommended childhood and adolescent immunization schedule in the U.S. as of January 2003. Types of vaccine administered to children and adolescents; Reasons behind the deferral of some doses of pneumococcal conjugate vaccine; Details of the National Childhood...

  • Reduction in erythromycin resistance in invasive pneumococci from young children in England and Wales. Henderson, Katherine L.; Muller-Pebody, Berit; Blackburn, Ruth M.; Johnson, Alan P. // Journal of Antimicrobial Chemotherapy (JAC);Feb2010, Vol. 65 Issue 2, p369 

    A letter to the editor is presented about a study of the effects of immunization with pneumococcal heptavalent conjugate vaccine (PCV7) based on data on pneumococcal bacteraemia and erythromycin susceptibility tests of children in England and Wales from 2000 to 2009.

  • Effects of Community-Wide Vaccination with PCV-7 on Pneumococcal Nasopharyngeal Carriage in The Gambia: A Cluster-Randomized Trial. Roca, Anna; Hill, Philip C.; Townend, John; Egere, Uzo; Antonio, Martin; Bojang, Abdoulie; Akisanya, Abiodun; Litchfield, Teresa; Nsekpong, David E.; Oluwalana, Claire; Howie, Stephen R. C.; Greenwood, Brian; Adegbola, Richard A. // PLoS Clinical Trials;Oct2011, Vol. 8 Issue 10, Special section p1 

    Background: Introduction of pneumococcal conjugate vaccines (PCVs) of limited valency is justified in Africa by the high burden of pneumococcal disease. Long-term beneficial effects of PCVs may be countered by serotype replacement. We aimed to determine the impact of PCV-7 vaccination on...

  • Independent Nurse: Recent research indicates need for change to immunisation schedule. Polak, Monika // GP: General Practitioner;12/2/2005, p93 

    The article reports that the childhood immunisation schedule looks set for a significant overhaul in the light of recent research. Professor Keith Cartwright, a member of the Joint Committee on Vaccination and Immunisation said that immunological evidence suggested additional booster doses are...

  • Pneumococcal 7-valent CRM197 vaccine conjugate.  // Reactions Weekly;Aug2014, Vol. 1516 Issue 1, p154 

    An abstract of the article "Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway," by A. Steens and colleagues is presented.

  • Herd immunity in adults improves value of paediatric vax.  // PharmacoEconomics & Outcomes News;12/3/2005, Issue 492, p9 

    The article presents information on an economic analysis which found that when the herd immunity effect on adults is considered, the cost effectiveness of pneumococcal conjugate vaccine in U.S. children improves. The results of the analysis was presented at the 43rd Annual Meeting of the...

  • How much has PCV reduced radiographic pneumonia? Burke, Michael G. // Contemporary Pediatrics;Mar2009, Vol. 26 Issue 3, p42 

    The article discusses research on the use of pneumococcal conjugate vaccine (PCV) to lessen incidence of radiographic pneumonia. It references a study by M. S. Rutman et al, published in a 2009 issue of "Pediatric Emergency Care." According to the study involving 889 young highly febrile...

  • Updated Recommendation From the Advisory Committee on Immunization Practices (ACIP) for Use of 7-Valent Pneumococcal Conjugate Vaccine (PCV7) in Children Aged 24-59 Months Who Are Not Completely Vaccinated.  // JAMA: Journal of the American Medical Association;5/7/2008, Vol. 299 Issue 17, p2020 

    The article presents updated changes to recommendations for the use of 7-valent pneumococcal conjugate vaccine (PCV7) for children between the ages of 24-59 months. The U.S. Advisory Committee on Immunization Practices is limiting routine vaccination to children aged 24-59 months who have...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics